Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Price:
9.51
USD
1.06%
Market Closed
Market Cap:
$262.1m
Balance Sheet
Balance Sheet Decomposition
Crescent Biopharma Inc (Pre-Reincorporation)
Crescent Biopharma Inc (Pre-Reincorporation)
Balance Sheet Decomposition is not available for
Crescent Biopharma Inc (Pre-Reincorporation)
Crescent Biopharma Inc (Pre-Reincorporation)
Balance Sheet
Crescent Biopharma Inc (Pre-Reincorporation)
Crescent Biopharma Inc (Pre-Reincorporation)
Currency: USD
| Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
28
|
17
|
2
|
55
|
47
|
40
|
124
|
210
|
158
|
137
|
90
|
48
|
42
|
11
|
|
| Cash Equivalents |
28
|
17
|
2
|
55
|
47
|
40
|
124
|
210
|
158
|
137
|
90
|
48
|
42
|
11
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
1
|
3
|
1
|
0
|
0
|
3
|
2
|
4
|
1
|
1
|
3
|
2
|
0
|
|
| Total Current Assets |
28
|
18
|
5
|
56
|
47
|
41
|
127
|
212
|
163
|
138
|
91
|
51
|
44
|
11
|
|
| PP&E Net |
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
3
|
2
|
1
|
1
|
0
|
|
| PP&E Gross |
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
4
|
3
|
2
|
1
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
2
|
2
|
2
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
1
|
1
|
0
|
2
|
2
|
2
|
2
|
0
|
1
|
0
|
|
| Total Assets |
29
N/A
|
18
-36%
|
5
-71%
|
57
+981%
|
49
-15%
|
42
-13%
|
129
+203%
|
215
+67%
|
168
-22%
|
143
-15%
|
94
-34%
|
52
-45%
|
45
-13%
|
11
-76%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
1
|
1
|
2
|
3
|
3
|
1
|
2
|
2
|
1
|
1
|
0
|
|
| Accrued Liabilities |
1
|
1
|
1
|
5
|
7
|
5
|
5
|
6
|
10
|
10
|
10
|
8
|
6
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
15
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Liabilities |
16
|
6
|
2
|
7
|
8
|
6
|
8
|
9
|
11
|
12
|
12
|
9
|
7
|
6
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
4
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
2
|
1
|
0
|
0
|
0
|
|
| Total Liabilities |
21
N/A
|
6
-71%
|
2
-59%
|
7
+171%
|
8
+23%
|
7
-11%
|
9
+25%
|
9
+6%
|
14
+47%
|
15
+6%
|
13
-13%
|
9
-30%
|
7
-22%
|
6
-16%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
56
|
53
|
63
|
74
|
87
|
119
|
152
|
201
|
258
|
310
|
373
|
420
|
456
|
494
|
|
| Additional Paid In Capital |
65
|
65
|
66
|
125
|
128
|
154
|
272
|
406
|
413
|
438
|
454
|
463
|
495
|
500
|
|
| Total Equity |
9
N/A
|
13
+47%
|
3
-77%
|
51
+1 652%
|
41
-20%
|
35
-13%
|
120
+239%
|
206
+72%
|
154
-25%
|
128
-17%
|
82
-36%
|
43
-47%
|
38
-10%
|
5
-86%
|
|
| Total Liabilities & Equity |
29
N/A
|
18
-36%
|
5
-71%
|
57
+981%
|
49
-15%
|
42
-13%
|
129
+203%
|
215
+67%
|
168
-22%
|
143
-15%
|
94
-34%
|
52
-45%
|
45
-13%
|
11
-76%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
1
|
1
|
1
|
19
|
19
|
23
|
34
|
43
|
44
|
49
|
52
|
54
|
1
|
1
|
|
| Preferred Shares Outstanding |
31
|
0
|
31
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
